Urodynamic effects of silodosin, a new a1a-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia

Neurourology and Urodynamics

Volumn 29, Issue 4, 2010, Pages 558-562

  Yamanishi, Tomonori ^a   Mizuno, Tomoya ^a   Tatsumiya, Katsuhisa ^a   Watanabe, Miho ^a   Kamai, Takao ^a   Yoshida, Ken Ichiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Alpha blockers; BOO; BPH; LUTS; Prospective; Silodosin; Urodynamics

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; SILODOSIN;

ADULT; AGED; ARTICLE; BLADDER CAPACITY; BLADDER NECK STENOSIS; CLINICAL ARTICLE; CYSTOMETRY; DIZZINESS; DRUG EFFECT; EJACULATION DISORDER; FLOW RATE; HUMAN; LOOSE FECES; LOWER URINARY TRACT SYMPTOM; MALE; MICTURITION; NOSE CONGESTION; OVERACTIVE BLADDER; PATIENT REFERRAL; PROSTATE HYPERTROPHY; PRURITUS; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; THIRST; THROMBOCYTE COUNT; URINE RETENTION; URODYNAMICS;

AGED; AGED, 80 AND OVER; HUMANS; INDOLES; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY BLADDER NECK OBSTRUCTION; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 77953551897     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20802     Document Type: Article

References (26)

1. 1-Adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008;15:193-199
2. Djavan B, Marberger M. Meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-3.
3. Djavan B, Chapple C, Marberger M, et al. State of the art on the efficacy and tolerability of alpha-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081-1088 (Pubitemid 39647042)
4. Yamanishi T, Yasuda K, Kamai T, et al. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Int J Urol 2004;11:501-509
5. Price DT, Schwinn DA, Lomasney JW, et al. Identification, quantification, and localization of mRNA for three distinct alphaA1 adrenergic receptor subtypes in human prostate. J Urol 1993;150:546-551
6. Kojima Y, Sasaki S, Shinoura H, et al. Change of expression levels of alph1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor- subtypeselective antagonist naftopidil in benign prostate hyperplasia patients. Prostate 2007;67:1285-1292
7. Yamanishi T, Tatssumiya K, Furuya N, et al. Long-term efficacy of tamsulosin in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in real-life practice. UroToday Int J 2009;2. doi:10.3834/ uij.1944-5784.2009.02.01.
8. Kawabe K, Yoshida M, Homma Y, for the Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebocontrolled, double-blind study in Japanese men. BJU Int 2006;98:1019-1024
9. Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: Pooled results of 2 phase 3 studies. J Urol 2009;181:2634-2640
10. 1-adrenoceptors and native tissues. Mol Pharmacol 1995;48: 250-258
11. Homma Y, Kawabe K, Tsukamoto T, et al. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int J Urol 1996;3:261-266 (Pubitemid 26264297)
12. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: Report from the standardization sub-committee of the international continence society. Neurourol Urodynam 2002;21: 167-178 (Pubitemid 34195211)
13. Homma Y, Kawabe K, Tsukamoto T, et al. Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int J Urol 1996;3:267-273 (Pubitemid 26264298)
14. Rossi C, Kortmann BB, Sonke GS, et al. α-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J Urol 2001; 165:38-41.
15. Barendrecht MM, Abrams P, Schumacher H, et al. Do alph1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 2008;27:226-230
16. Nishino Y, Masue T, Miwa K. Comparison of two α1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: A randomized cross over study. BJU Int 2006;97:747-751
17. Momose H, Hosokawa Y, Kishino T, et al. Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs Today 2007;43:1-10.
18. Malloy BJ, Price DT, Price RR, et al. α1-Adrenergic receptor subtypes in human detrusor. J Urol 1998;160:937-943
19. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003;170:649-653
20. Smith MS, Schambra UB, Wilson KH, et al. Alpha1-adrenergic receptors in human spinal cord: Specific localized expression on mRNA encoding α1-adrenergic receptor subtypes at four distinct levels. Brain Res Mol Brain Res 1999;63:254-261
21. Sugaya K, Nishijima S, Miyazato M, et al. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci Lett 2002;328:74-76
22. Yoshiyama M, DeGroat WC. Role of spinal α1-adrenoceptor subtypes in the bladder reflex in anesthetized rats. Am J Physiol 2001;280:R1414-R1419.
23. Tatemichi S, Akiyama K, Kobayashi M, et al. A selective α1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 2006;176:1236-1241
24. Pinggera GM, Mitterberger M, Pallwein L, et al. Alpha-blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int 2007;101:319-324
25. Rudner XL, Berkowitz DE, Booth JV, et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 1999;100:2336-2343
26. Tanaka Y, Masumori N, Itoh N, et al. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. J Urol 2001;167:2492-2495